Director AstraZeneca, Chemical Development Macclesfield, England, United Kingdom
Current oligonucleotide manufactures have long and complex supply chains covering amidite synthesis, oligo assembly, purification, isolation and formulation. The current state of the art in oligonucleotide production has an associated cost and waste burden that is unsustainable in the future as the demand for oligonucleotides increases. This presentation looks at the interactions between control strategy, cost and sustainability across substance and product. By considering these interactions it will describe how long term viability can be built in to the design of manufacturing and supply.
understand how substance and product manufactures can be linked in oligonucleotides
discuss the key sustainability challenges for large scale oligonucleotide manufacture
understand how a viable control strategy can be built for oligonucleotides